Cumulative incidence and severity of AEs, SAEs, and lab abnormalities as a measure of safety and tolerability. 2 years [clinicaltrials_resource:2fb2273d736396ab98a80abd27ac538d]
The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.
Dry Powder Inhaled Dose:
Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Cumulative incidence and severity of AEs, SAEs, and lab abnormalities as a measure of safety and tolerability. 2 years [clinicaltrials_resource:2fb2273d736396ab98a80abd27ac538d]
The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.
Dry Powder Inhaled Dose:
Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction.
Bio2RDF identifier
2fb2273d736396ab98a80abd27ac538d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2fb2273d736396ab98a80abd27ac538d
measure [clinicaltrials_vocabulary:measure]
Cumulative incidence and sever ...... re of safety and tolerability.
time frame [clinicaltrials_vocabulary:time-frame]
description
The DAS181-F02 nebulized formu ...... lized formulation instruction.
identifier
clinicaltrials_resource:2fb2273d736396ab98a80abd27ac538d
title
Cumulative incidence and sever ...... fety and tolerability. 2 years
@en
type
label
Cumulative incidence and sever ...... 2273d736396ab98a80abd27ac538d]
@en